Mayo Clinic Florida, USA.
MAbs. 2010 Nov-Dec;2(6):607-12. doi: 10.4161/mabs.2.6.13586. Epub 2010 Nov 1.
The use of antibodies in transplantation dates to 1986 when muromonab CD3, a monoclonal antibody (mAb) targeting CD3, was first approved for prevention and treatment of renal allograft rejection. These agents have largely been used in a brief adjunctive manner to provide immunosuppression during the initial period after solid organ transplantation or during an episode of acute rejection. Recent advances in our understanding of transplant immunology have allowed emergence of numerous new mAbs, targeting co-stimulatory signals, cell surface receptors and novel protein constructs. During the next decade, transplant professionals will increasingly require knowledge of the mechanisms and pharmacologic characteristics of these novel therapeutic agents.
抗体在移植中的应用可以追溯到 1986 年，当时靶向 CD3 的单克隆抗体（mAb）muromonab CD3 首次被批准用于预防和治疗肾移植排斥反应。这些药物主要在实体器官移植后的初始阶段或急性排斥反应期间以短暂辅助方式使用，以提供免疫抑制。我们对移植免疫学的理解的最新进展使得许多新的 mAb 得以出现，这些 mAb 针对共刺激信号、细胞表面受体和新型蛋白质构建体。在未来十年，移植专业人员将越来越需要了解这些新型治疗药物的作用机制和药理学特征。
